Essentials of Antimicrobial Stewardship, 2/e

This second edition is lauched with humongous updates on topics added/revised such as: - 2023 to 2025 CLSI/EUCAST updates (500 plus corrections/updates are added with complete update on 75 plus tables in these chapters) - Newer Antimicrobials - 42 new antibiotics are discussed new in this new edition - Updates on Treatment guidelines and Dosing Regimens - New Duke's criteria 2023 - Module on interpretation for AES modification of VITEK AST - Practical Module in Validation of Antibiogram - Practical Module on Pathogen directed AMS audit 1000 plus corrections/updates are added with complete revision/correction of 300 plus tables in the book Major revision in interpretation of AST Chapter as per latest guidelines from CLSI and EUCAST incorporating several updates such as o Tier system of CLSI, update in the list of SDD and ECV o Update in the clinical breakpoints including Salmonella/Shigella breakpoint table o Update in the reporting of fosfomycin, aminoglycosides, CZA-ATM synergy o Update on AST reporting of B. cepacia, B. pseudomallei, Stenotrophomonas, A. baumannii o Update on treatment recommendations for invasive enterococcal infections Updates on Treatment guidelines and Dosing Regimens New Duke's criteria 2023 for IE Major update: A new Module on Decision to be taken on VITEK-AES modifications . Major update: A new Practical Module in Validation of Antibiogram based on general acceptable S% rules (with new exercise) Major update: Practical Module on Pathogen-directed (PD) AMS audit Updates in list of drugs in AWaRe classification Revised definitions on antimicrobial consumption (AMC) and antimicrobial use (AMU) Major updates on fosfomycin and CZA-ATM synergy testing methods, AmpC detection methods etc. Major updates on BMQ and MIC guiding tables and selective reporting 40 newer antimicrobials have been incorporated in every chapter of Antimicrobial Section such as newer lactams and BLBLI, newer aminoglycosides, newer tetracyclines, newer quinolones and several novel antimicrobials. A major revision has been carried on treatment of tuberculosis chapter. Major revision on chapters on Targeted therapy for GNB and GPC .…